Careers at BD

Pfitzer et al. (2013) identify BD’s development of a needleless injection system as an example of leading businesses’ role in creating shared value. The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes. In certain places, BD Medical also offers consulting and analytics related services. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products.

Q-Syte Luer and IV Catheter partial recall

2015 BD became the first to integrate IV pumps with electronic health records. 2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized. 2019 BD launched the first venous stent to treat iliofemoral venous occlusive disease. 2014 BD launched the first FDA-approved drug coated balloon for peripheral artery disease.

Sign Up for Job Alerts

• In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month.
• 1947 BD hired Joseph Kleiner, who brings his multi-fit syringe and his idea for the evacuated tube.
• 2015 BD became the first to integrate IV pumps with electronic health records.
• 1906 BD opened the first syringe and needle factory in the United States.
• Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare.

The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton. Embecta Corporation is a standalone public company focused on diabetes care. BD can help you improve surgical outcomes and lower costs Surgical efficiency, patient safety and outcomes, procedural cost management BD can help you identify potential “at-risk” patients, empower clinical intervention, and advance health system insights BD can help you optimize clinical effectiveness to help drive improvement in patient outcomes

R. Bard, a medical device company founded in 1907 in Covington, Georgia. BD and its affiliates and subsidiaries (BD) do not accept any liability for fees for resumes from recruiters or employment agencies (“Agency”), without a binding, written recruitment agreement between BD and Agency describing the services and specific job openings (“Agreement”). They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.

“Jack” Howe joins BD and becomes integral to developing sterility control procedures and refining the process for manufacturing disposable syringes and needles. 1962 BD launched the first mass production of syringes and needles. 2007 BD participates in PEPFAR, the U.S. government’s global effort to combat HIV and the largest global health program devoted to a single disease. 2007 BD participates in PEPFAR, the U.S. government’s global effort to combat HIV and the largest global health program devoted to a single disease.\r\n As one of the largest global medical technology companies, we develop solutions that improve diagnostics, enhance care and transform lives around the world.

1925 BD acquired the Yale™ Luer-Lok™ — the first simple, secure method for attaching and removing a needle from a syringe. 1954 Production of the first disposable syringes to be used in the Salk Polio vaccine trial takes place. 1988 BD launched the first safety engineered syringe.

1991 BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa. 1995 A joint venture was established in China to produce medical products for China. 1995 A jaya 9 betting joint venture was established in China to produce medical products for China.\r\n

The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. We know that possibilities are endless when people feel supported and inspired.

2015 BD became the first to integrate IV pumps with electronic health records.\r\n 2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized.\r\n 2019 BD launched the first venous stent to treat iliofemoral venous occlusive disease.\r\n 2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process. 2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution. Bard might be a scam, please verify by searching for the posting on the careers page or contact us at